Regard, founded in 2017 and based in Los Angeles, set out to address a quiet but consequential problem in hospital medicine: relevant clinical information is often buried in the chart, and busy physicians can miss diagnoses or fail to document conditions that affect both patient care and hospital finances. Regard's AI co-pilot reads the patient's data directly within the EHR, analyzes it, and surfaces potential diagnoses the care team may have overlooked, while also generating clinical documentation to reduce the manual burden on physicians.
The dual value proposition — better care and better economics — is central to Regard's positioning. By identifying missed or undocumented conditions, the system helps clinicians treat patients more completely and helps hospitals capture revenue they would otherwise lose to incomplete documentation. Since its launch, Regard reports that its technology has surfaced more than three million diagnoses to care teams and generated more than $50 million in incremental revenue for enterprise health system partners, including Banner Health and Sentara.
In July 2024 Regard announced a $61M Series B led by Oak HC/FT, with participation from Cedars-Sinai Health Ventures and existing investors TenOneTen, Calibrate Ventures, and Techstars, valuing the company at $350M. The funding was earmarked to accelerate development of the core clinical insights platform, invest in fundamental research on large language models, and expand the product beyond inpatient settings into new care environments. The involvement of Cedars-Sinai underscored the clinical credibility that matters when selling AI tools that influence diagnostic decisions.
Regard's customers are hospitals and health systems where the combination of diagnostic support, documentation automation, and revenue integrity creates a clear return on investment. Its strategic differentiation is the depth of integration into the EHR and the focus on surfacing actionable clinical insight rather than simply transcribing encounters. As health systems face continued financial pressure and clinician shortages, tools that simultaneously improve documentation accuracy, reduce administrative load, and catch missed illness occupy a particularly valuable position — and Regard's track record of measurable clinical and financial impact gives it a strong footing in the inpatient AI market.